NCT01789892

Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer

FDG PET/CT: Reducing False Positive Mediastinal Uptake by Premedicating With Methylprednisolone

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Ohio State University Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether giving an anti-inflammatory medication (corticosteroid) prior to a positron emission tomography scan (PET) scan may reduce or eliminate false findings related to inflammation

Detailed description

PRIMARY OBJECTIVES: I. To assess whether premedication with a corticosteroid may reduce false positive findings on fluorodeoxyglucose (fludeoxyglucose F 18 \[FDG\[) PET/computed tomography (CT) scans in lung cancer patients, by reducing radiotracer uptake in thoracic lymph nodes related to inflammation. OUTLINE: Within 1-14 days of undergoing standard FDG PET/CT scan, patients receive methylprednisolone intravenously (IV) and then undergo a second FDG PET/CT scan. After completion of study treatment, patients are followed up for 2 years.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	methylprednisolone	Given IV
RADIATION	fludeoxyglucose F 18	Undergo FDG PET/CT scan
PROCEDURE	positron emission tomography	Undergo FDG PET/CT scan
PROCEDURE	computed tomography	Undergo FDG PET/CT scan

Timeline

• Start date: 2011-06-01
• Primary completion: 2013-01-01
• Completion: 2013-01-01
• First posted: 2013-02-12
• Last updated: 2018-06-28